Multiple strand displacement amplification of mitochondrial DNA from clinical samples

Samantha Maragh, John P. Jakupciak, Paul D. Wagner, William N. Rom, David Sidransky, Sudhir Srivastava, Catherine D. O'Connell

Research output: Contribution to journalArticle

Abstract

Background: Whole genome amplification (WGA) methods allow diagnostic laboratories to overcome the common problem of insufficient DNA in patient specimens. Further, body fluid samples useful for cancer early detection are often difficult to amplify with traditional PCR methods. In this first application of WGA on the entire human mitochondrial genome, we compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that performed without genome amplification. We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence. Methods: DNA was isolated from clinical samples and sent to NIST. Samples were amplified by PCR and those with no visible amplification were re-amplified using the Multiple Displacement Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for mitochondrial DNA sequence to compare sequence concordance of the WGA samples with respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA amplification for both nuclear and mtDNA. Results: In total, 19 samples were compared and the concordance rate between WGA and native mtDNA sequences was 99.995%. All of the cancer associated mutations in the native mtDNA were detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the sample, 13 new heteroplasmies were detected in the WGA material. Conclusion: Genetic screening of mtDNA amplified by WGA is applicable for the detection of cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately detecting mtDNA point mutations associated with cancer.

Original languageEnglish (US)
Article number7
JournalBMC Medical Genetics
Volume9
DOIs
StatePublished - Feb 7 2008

Fingerprint

Mitochondrial DNA
Genome
DNA
Neoplasms
Polymerase Chain Reaction
Mutation
Mitochondrial Genome
Genetic Testing
Body Fluids
Human Genome
DNA Sequence Analysis
Early Detection of Cancer
Point Mutation
Real-Time Polymerase Chain Reaction

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)

Cite this

Maragh, S., Jakupciak, J. P., Wagner, P. D., Rom, W. N., Sidransky, D., Srivastava, S., & O'Connell, C. D. (2008). Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Medical Genetics, 9, [7]. https://doi.org/10.1186/1471-2350-9-7

Multiple strand displacement amplification of mitochondrial DNA from clinical samples. / Maragh, Samantha; Jakupciak, John P.; Wagner, Paul D.; Rom, William N.; Sidransky, David; Srivastava, Sudhir; O'Connell, Catherine D.

In: BMC Medical Genetics, Vol. 9, 7, 07.02.2008.

Research output: Contribution to journalArticle

Maragh, Samantha ; Jakupciak, John P. ; Wagner, Paul D. ; Rom, William N. ; Sidransky, David ; Srivastava, Sudhir ; O'Connell, Catherine D. / Multiple strand displacement amplification of mitochondrial DNA from clinical samples. In: BMC Medical Genetics. 2008 ; Vol. 9.
@article{1f54140782964feb835d86847aa8be6e,
title = "Multiple strand displacement amplification of mitochondrial DNA from clinical samples",
abstract = "Background: Whole genome amplification (WGA) methods allow diagnostic laboratories to overcome the common problem of insufficient DNA in patient specimens. Further, body fluid samples useful for cancer early detection are often difficult to amplify with traditional PCR methods. In this first application of WGA on the entire human mitochondrial genome, we compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that performed without genome amplification. We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence. Methods: DNA was isolated from clinical samples and sent to NIST. Samples were amplified by PCR and those with no visible amplification were re-amplified using the Multiple Displacement Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for mitochondrial DNA sequence to compare sequence concordance of the WGA samples with respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA amplification for both nuclear and mtDNA. Results: In total, 19 samples were compared and the concordance rate between WGA and native mtDNA sequences was 99.995{\%}. All of the cancer associated mutations in the native mtDNA were detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the sample, 13 new heteroplasmies were detected in the WGA material. Conclusion: Genetic screening of mtDNA amplified by WGA is applicable for the detection of cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately detecting mtDNA point mutations associated with cancer.",
author = "Samantha Maragh and Jakupciak, {John P.} and Wagner, {Paul D.} and Rom, {William N.} and David Sidransky and Sudhir Srivastava and O'Connell, {Catherine D.}",
year = "2008",
month = "2",
day = "7",
doi = "10.1186/1471-2350-9-7",
language = "English (US)",
volume = "9",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Multiple strand displacement amplification of mitochondrial DNA from clinical samples

AU - Maragh, Samantha

AU - Jakupciak, John P.

AU - Wagner, Paul D.

AU - Rom, William N.

AU - Sidransky, David

AU - Srivastava, Sudhir

AU - O'Connell, Catherine D.

PY - 2008/2/7

Y1 - 2008/2/7

N2 - Background: Whole genome amplification (WGA) methods allow diagnostic laboratories to overcome the common problem of insufficient DNA in patient specimens. Further, body fluid samples useful for cancer early detection are often difficult to amplify with traditional PCR methods. In this first application of WGA on the entire human mitochondrial genome, we compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that performed without genome amplification. We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence. Methods: DNA was isolated from clinical samples and sent to NIST. Samples were amplified by PCR and those with no visible amplification were re-amplified using the Multiple Displacement Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for mitochondrial DNA sequence to compare sequence concordance of the WGA samples with respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA amplification for both nuclear and mtDNA. Results: In total, 19 samples were compared and the concordance rate between WGA and native mtDNA sequences was 99.995%. All of the cancer associated mutations in the native mtDNA were detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the sample, 13 new heteroplasmies were detected in the WGA material. Conclusion: Genetic screening of mtDNA amplified by WGA is applicable for the detection of cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately detecting mtDNA point mutations associated with cancer.

AB - Background: Whole genome amplification (WGA) methods allow diagnostic laboratories to overcome the common problem of insufficient DNA in patient specimens. Further, body fluid samples useful for cancer early detection are often difficult to amplify with traditional PCR methods. In this first application of WGA on the entire human mitochondrial genome, we compared the accuracy of mitochondrial DNA (mtDNA) sequence analysis after WGA to that performed without genome amplification. We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence. Methods: DNA was isolated from clinical samples and sent to NIST. Samples were amplified by PCR and those with no visible amplification were re-amplified using the Multiple Displacement Amplificaiton technique of whole genome amplification. All samples were analyzed by mitochip for mitochondrial DNA sequence to compare sequence concordance of the WGA samples with respect to native DNA. Real-Time PCR analysis was conducted to determine the level of WGA amplification for both nuclear and mtDNA. Results: In total, 19 samples were compared and the concordance rate between WGA and native mtDNA sequences was 99.995%. All of the cancer associated mutations in the native mtDNA were detected in the WGA amplified material and heteroplasmies in the native mtDNA were detected with high fidelity in the WGA material. In addition to the native mtDNA sequence present in the sample, 13 new heteroplasmies were detected in the WGA material. Conclusion: Genetic screening of mtDNA amplified by WGA is applicable for the detection of cancer associated mutations. Our results show the feasibility of this method for: 1) increasing the amount of DNA available for analysis, 2) recovering the identical mtDNA sequence, 3) accurately detecting mtDNA point mutations associated with cancer.

UR - http://www.scopus.com/inward/record.url?scp=41149141016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149141016&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-9-7

DO - 10.1186/1471-2350-9-7

M3 - Article

VL - 9

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

M1 - 7

ER -